JT001
JT001 (NLRP3-IN-19) is a potent, specific and orally active inhibitor of NLRP3. JT001 can inhibit NLRP3 inflammasome assembly, resulting in the inhibition of cytokine release and the prevention of pyroptosis. JT001 can be used for the research of nonalcoholic steatohepatitis and liver fibrosis[1].
Product Specifications
CAS Number
2238819-65-1
Product Name Alternative
NLRP3-IN-19
UNSPSC
12352005
Target
NOD-like Receptor (NLR)
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jt001.html
Solubility
10 mM in DMSO
Smiles
O=C(NS(=O)(C1=C2OCCCN2N=C1)=O)NC3=C4CCCC4=CC5=C3CCC5
Molecular Formula
C19H22N4O4S
Molecular Weight
402.47
References & Citations
[1]Povero D, et, al. Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis. J Pharmacol Exp Ther. 2023 Aug;386 (2) :242-258.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 3
Isoform
NLRP3
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940718-500 1x 500 µL
HER-2 / CD340 (HRB2/718), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC942946-100 1x 100 µL
TLE1 (Synovial Sarcoma Marker) (TLE1/2946R), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 